Total
0
Shares
Mesoblast (ASX:MSB) - Managing Director & CEO, Silviu Itescu (centre) - The Market Herald
Managing Director & CEO, Silviu Itescu (centre)
Source: Mesoblast
  • Mesoblast's (MSB) lead product candidate has come out on top at the Fierce Innovation Awards
  • The company's remestemcel-L treatment, which has recently been tested against acute respiratory distress syndrome (ARDS) in COVID-19 patients, won the prestigious 'Fierce Biotech Innovation of the Year' award
  • Remestemcel-L is also being trialled as a treatment for children with steroid-refractory acute graft versus host disease (SR-aGVHD)
  • This is a potentially life-threatening complication which can develop when a patient undergoes a bone marrow transplant
  • Currently, the drug is under priority review with the U.S. Food and Drug Administration (FDA)
  • The dual-listed healthcare stock has a pipeline of other clinical treatments and is primarily focussed on cellular medicines
  • Following the news, shares in the ASX 200-lister shot up 7.97 per cent to trade for just over $5 each

Mesoblast's (MSB) lead product candidate has come out on top at the Fierce Innovation Awards.

The peer-reviewed awards program is the brainchild of the FierceBiotech and FiercePharma publisher, a way to celebrate the best and brightest in the biotech space.

The company's remestemcel-L treatment, which has recently been tested against acute respiratory distress syndrome (ARDS) in COVID-19 patients, won the prestigious 'Fierce Biotech Innovation of the Year' award.

Remestemcel-L is also being trialled as a treatment for children with steroid-refractory acute graft versus host disease (SR-aGVHD), a potentially life-threatening complication when a patient undergoes a bone marrow transplant.

Currently, the drug is under priority review with the U.S. Food and Drug Administration (FDA). The major clinical body is evaluating the treatment, and, if approved, remestemcel-L could launch in the states as soon as this year. This treatment is already available in Japan under the 'RYONCIL' label.

“This important award is recognition of Mesoblast’s leadership as an innovator in the cell therapy industry, and of the potential for remestemcel-L to profoundly impact the lives of children suffering with SR-aGVHD," Mesoblast CEO Dr Silviu Itescu commented.

The dual-listed healthcare stock has a pipeline of other clinical treatments and is primarily focussed on cellular medicines.

Following the news, shares in the ASX 200-lister shot up 7.97 per cent to trade for just over $5 each at 11:35 am AEST.


Subscribe


MSB by the numbers
More From The Market Herald
PolyNovo (ASX:PNV) - CEO, Paul Brennan - The Market Herald

" PolyNovo (ASX:PNV) selects Finnish distributor

Healthcare giant PolyNovo (PNV) has selected Innova Medical Oy to distribute its clinical wound treatment in Finland.
Medlab (ASX:MDC)- CEO, Sean Hall - The Market Herald

" Medlab Clinical (ASX:MDC) recieves Australian patent for NanoCelle

Biotech company Medlab Clinical (MDC) has been granted an Australian patent for its NanoCelle delivery platform.
Proteomics receives CE Mark for kidney disease test

" BARD1 Life Sciences’ (ASX:BD1) ovarian cancer test kit passes muster

BARD1 Life Sciences (BD1) has received positive results from a trial of its improved ovarian cancer test kit.
Recce Pharmaceuticals (ASX:RCE) - CEO, James Graham - The Market Herald

" Recce Pharmaceuticals (ASX:RCE) completes $27.95M capital raise

Recce Pharmaceuticals (RCE) has completed its capital raise and successfully raised $27.95 million.